|
ORs and 95% CIs for HPV-16 positive ICC according to HLA. |
|||||
| Controls (n = 257) |
HPV-16 Cases (n = 112) |
||||
|
|
|
||||
| HLA |
Crude |
Adjustedd |
|||
|
|
|
||||
| C/Na |
C/N |
ORb |
OR |
CIc |
|
|
|
|||||
| DQA1 |
|||||
| *0102 |
80/177 |
39/73 |
1.18 |
1.22 |
0.73–2.04 |
| DQB1 |
|||||
| *0501 |
71/186 |
25/87 |
0.75 |
0.72 |
0.40–1.27 |
| *06 |
87/170 |
46/66 |
1.36 |
1.32 |
0.80–2.17 |
| *0602 |
44/213 |
30/82 |
1.77 |
1.59 |
0.89–2.83 |
| DRB1 |
|||||
| *01 |
52/205 |
22/90 |
0.96 |
0.89 |
0.49–1.64 |
| *0102 |
29/228 |
12/100 |
0.94 |
0.83 |
0.38–1.79 |
| *04 |
74/183 |
23/89 |
0.64 |
0.67 |
0.38–1.19 |
| *13 |
61/196 |
19/93 |
0.66 |
0.78 |
0.42–1.45 |
| *1302 |
27/230 |
4/108 |
0.32 |
0.43 |
0.14–1.32 |
| DRB1-DQB1 haplotypes |
|||||
| 0102–0501 |
29/228 |
12/100 |
0.94 |
0.59 |
0.23–1.51 |
| 15-0602 |
33/224 |
28/84 |
2.26 |
2.12 |
1.15–3.93 |
| 1503-0602 |
14/243 |
15/97 |
2.68 |
2.77 |
1.20–6.39 |
| 08041-0301 |
5/252 |
3/109 |
1.39 |
0.88 |
0.14–5.47 |
| 09012-0201/02 |
3/254 |
3/109 |
2.33 |
3.02 |
0.56–16.29 |
|
a) C/N: Carriers/Non carriers; b) OR: Odds Ratio; c) CI: Confidence Interval; d) Adjusted for age and ethnic group. | |||||
de Araujo Souza et al. BMC Cancer 2008 8:246 doi:10.1186/1471-2407-8-246 |
|||||